Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating margetuximab plus chemotherapy in Chinese patients with HER2-positive metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Margetuximab (margetuximab)

Snippet

Sponsor: Zai Lab (Shanghai) Co., Ltd. | Conditions: Breast Cancer Metastatic | Phase 2 | Status: UNKNOWN